SYS-CON MEDIA Authors: Pat Romanski, Yeshim Deniz, Janakiram MSV, Liz McMillan, Elizabeth White

News Feed Item

Tetra Bio-Pharma Signs Landmark Commercialization Term Sheet for its Lead Pharmaceutical Product, PPP001, in Israel

OTTAWA, ONTARIO -- (Marketwired) -- 04/24/18 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP) (OTCQB:TBPMF), announced today that the Company has signed a first binding term sheet for the marketing and distribution of PPP001 in Israel with Kamada Ltd., a leading pharmaceutical company. The signing of a Definitive Distribution Agreement is expected to follow shortly. PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription.

This first international market commercialization agreement represents a significant milestone and a validation of Tetra Bio-Pharma's business model with a leading Israel-based pharmaceutical company. Israel, like Canada, is considered one of the world leaders in the production and development of cannabinoid-based products. Kamada is a company with two FDA-approved products and an Israeli-based distribution segment that has demonstrated continued growth. Tetra Bio-Pharma intends to work closely with Kamada as PPP001 advances towards regulatory approval and commercial launch in Israel.

Under the terms of the anticipated final agreement, Kamada will be responsible for registering the product, as well as all marketing and distribution, in Israel. Tetra will be eligible to receive certain milestone payments and an undisclosed percentage of the sales of PPP001 generated by Kamada in Israel.

About PPP001

On April 4, 2018, Tetra Bio-Pharma officially started the Phase 3 trial for PPP001 indicated for terminal stage cancer patients with a goal to improving the quality of life of these patients as well as minimizing their pain. PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription.

About Tetra Bio-Pharma: Tetra Bio-Pharma (TSX VENTURE:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products. Tetra Bio-Pharma is currently developing a pipeline of five cannabinoid-based products using different delivery systems such as smokable pellets, oral tablets, eye drops and topical ointments. More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Contacts:
Tetra Bio-Pharma Inc.
Robert (Bob) Béchard
Vice President Finance and Business Development
[email protected]
M: +1 514 817-2514

For media information, please contact:
Daniel Granger
[email protected]
ACJ Communication
O: +1 514 840 7990
M: +1 514 232 1556

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Docker and Kubernetes are key elements of modern cloud native deployment automations. After building your microservices, common practice is to create docker images and create YAML files to automate the deployment with Docker and Kubernetes. Writing these YAMLs, Dockerfile descriptors are really painful and error prone.Ballerina is a new cloud-native programing language which understands the architecture around it - the compiler is environment aware of microservices directly deployable into infra...
Only the most exceptional IBMers are appointed with the rare distinction of IBM Fellow, the highest technical honor in the company. Shankar has also received the prestigious Outstanding Technical Achievement Award three times - an accomplishment befitting only the most innovative thinkers. Shankar Kalyana is among the most respected strategists in the global technology industry. As CTO, with over 32 years of IT experience, Mr. Kalyana has architected, designed, developed, and implemented custom ...
At CloudEXPO Silicon Valley, June 24-26, 2019, Digital Transformation (DX) is a major focus with expanded DevOpsSUMMIT and FinTechEXPO programs within the DXWorldEXPO agenda. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of business. Only 12% still survive. Similar percentages are found throug...
10ZiG Technology is a leading provider of endpoints for a Virtual Desktop Infrastructure environment. Our fast and reliable hardware is VMware, Citrix and Microsoft ready and designed to handle all ranges of usage - from task-based to sophisticated CAD/CAM users. 10ZiG prides itself in being one of the only companies whose sole focus is in Thin Clients and Zero Clients for VDI. This focus allows us to provide a truly unique level of personal service and customization that is a rare find in th...
As you know, enterprise IT conversation over the past year have often centered upon the open-source Kubernetes container orchestration system. In fact, Kubernetes has emerged as the key technology -- and even primary platform -- of cloud migrations for a wide variety of organizations. Kubernetes is critical to forward-looking enterprises that continue to push their IT infrastructures toward maximum functionality, scalability, and flexibility. As they do so, IT professionals are also embr...

CloudBees, Inc., the hub of enterprise Jenkins and DevOps, today announced a major investment in Kubernetes technology across all areas of the business. CloudBees has made Kubernetes a key part of its lon...

Signs of a shift in the usage of public clouds are everywhere. Previously, as organizations outgrew old IT methods, the natural answer was to try the public cloud approach; however, the public platform alone is not a complete solution. Complaints include unpredictable/escalating costs and mounting security concerns in the public cloud. Ultimately, public cloud adoption can ultimately mean a shift of IT pains instead of a resolution. That's why the move to hybrid, custom, and multi-cloud will ...
The Japan External Trade Organization (JETRO) is a non-profit organization that provides business support services to companies expanding to Japan. With the support of JETRO's dedicated staff, clients can incorporate their business; receive visa, immigration, and HR support; find dedicated office space; identify local government subsidies; get tailored market studies; and more.
Signs of a shift in the usage of public clouds are everywhere Previously, as organizations outgrew old IT methods, the natural answer was to try the public cloud approach; however, the public platform alone is not a complete solutionThe move to hybrid, custom, and multi-cloud will become more and more prevalent At the heart of this technology trend exists a custom solution to meet the needs and concerns of these organizations, including compliance, security, and cost issues Blending Ser...
While a hybrid cloud can ease that transition, designing and deploy that hybrid cloud still offers challenges for organizations concerned about lack of available cloud skillsets within their organization. Managed service providers offer a unique opportunity to fill those gaps and get organizations of all sizes on a hybrid cloud that meets their comfort level, while delivering enhanced benefits for cost, efficiency, agility, mobility, and elasticity.
Serverless Computing or Functions as a Service (FaaS) is gaining momentum. Amazon is fueling the innovation by expanding Lambda to edge devices and content distribution network. IBM, Microsoft, and Google have their own FaaS offerings in the public cloud. There are over half-a-dozen open source serverless projects that are getting the attention of developers.
If you are part of the cloud development community, you certainly know about “serverless computing,” almost a misnomer. Because it implies there are no servers which is untrue. However the servers are hidden from the developers. This model eliminates operational complexity and increases developer productivity. We came from monolithic computing to client-server to services to microservices to the serverless model. In other words, our systems have slowly “dissolved” from monolithic to function-...
Docker is sweeping across startups and enterprises alike, changing the way we build and ship applications. It's the most prominent and widely known software container platform, and it's particularly useful for eliminating common challenges when collaborating on code (like the "it works on my machine" phenomenon that most devs know all too well). With Docker, you can run and manage apps side-by-side - in isolated containers - resulting in better compute density. It's something that many developer...
The KCSP program is a pre-qualified tier of vetted service providers that offer Kubernetes support, consulting, professional services and training for organizations embarking on their Kubernetes journey. The KCSP program ensures that enterprises get the support they're looking for to roll out new applications more quickly and more efficiently than before, while feeling secure that there's a trusted and vetted partner that's available to support their production and operational needs.
When a company wants to develop an application, it must worry about many aspects: selecting the infrastructure, building the technical stack, defining the storage strategy, configuring networks, setting up monitoring and logging, and on top of that, the company needs to worry about high availability, flexibility, scalability, data processing, machine learning, etc. Going to the cloud infrastructure can help you solving these problems to a level, but what if we have a better way to do things. ...